TheEdgeResearch
Home / Stocks / JAGX

Jaguar Health, Inc. (JAGX)

NASDAQ Healthcare Biotechnology
$0.78 ▼ -0.45%
Market Cap
$51,973
Sector
Healthcare
Industry
Biotechnology
Beta
-0.05
52-Wk Range
0.7251-91
CEO
Lisa A. Conte
Country
US
Currency
USD

Jaguar Health, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Francisco, CA, US. The stock last traded at $0.78, down 0.45% on the session, giving a market capitalisation of $51,973. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -116.2%. Its beta of -0.05 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.00
Price / Sales
0.00
Price / Book
-0.03
EV / EBITDA
-0.97
Gross margin
85.1%
Operating margin
-86.3%
Net margin
-116.2%
Return on equity
Debt / equity
-3.09
Current ratio
0.50
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
47
IPO date
2015-05-12
Headquarters
San Francisco, CA, US
About Jaguar Health, Inc.

Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.

Comparable companies

Jaguar Health, Inc. is most often compared with the following Healthcare names:

BDRXCANFCLDICNSPGNPXGRIINMKZIASILOSXTP
More research on JAGX
JAGX technical analysis JAGX TheEdge Score Compare against peers
Open full interactive analysis & DCF →